Gefurulimab is under clinical development by Alexion Pharmaceuticals and currently in Phase III for Myasthenia Gravis.

CABA-201 is under development for the treatment of B cell-mediated autoimmune diseases such as idiopathic inflammatory myopathy, systemic lupus erythematous, anti-synthetase syndrome, dermatomyositis ...

Stine, MD, MPH, and Brooke Mills, MD, discuss how rheumatologists support the sexual & reproductive health needs of their ...

Objectives Risk prediction for patients with polymyositis/dermatomyositis-associated interstitial lung disease (PM/DM-ILD) is challenging due to heterogeneity in the ...

including steroid treatment algorithms, and using a composite primary endpoint which is likely to include BILAG. Trial registration number NCT00203151. Edratide demonstrated efficacy in one and ...

Cartesian Therapeutics said it has received rare pediatric disease designation from the U.S. Food and Drug Administration for its Descartes-08 treatment of juvenile dermatomyositis.

has granted Rare Pediatric Disease Designation to Descartes-08 for the treatment of juvenile dermatomyositis (JDM). Descartes-08, Cartesian’s lead mRNA cell therapy candidate, is an autologous ...

Descartes-08, Cartesian’s lead mRNA cell therapy candidate, is an autologous mRNA-engineered chimeric antigen receptor T-cell therapy (mRNA CAR-T) product candidate targeting B-cell maturation antigen ...